Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Upregulation of NFKBIZ affects bladder cancer progression via the PTEN/PI3K/Akt signaling pathway.

Tytuł:
Upregulation of NFKBIZ affects bladder cancer progression via the PTEN/PI3K/Akt signaling pathway.
Autorzy:
Xu T; Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Rao T; Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Yu WM; Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Ning JZ; Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Yu X; Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Zhu SM; Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Yang K; Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Bai T; Department of Urology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430060, P.R. China.
Cheng F; Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Źródło:
International journal of molecular medicine [Int J Mol Med] 2021 Jun; Vol. 47 (6). Date of Electronic Publication: 2021 Apr 28.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Athens, Greece : D.A. Spandidos, [1998-
MeSH Terms:
Disease Progression*
Adaptor Proteins, Signal Transducing/*genetics
PTEN Phosphohydrolase/*metabolism
Phosphatidylinositol 3-Kinases/*metabolism
Proto-Oncogene Proteins c-akt/*metabolism
Up-Regulation/*genetics
Urinary Bladder Neoplasms/*genetics
Urinary Bladder Neoplasms/*pathology
Adaptor Proteins, Signal Transducing/metabolism ; Aged ; Animals ; Cell Line, Tumor ; Cell Movement/genetics ; Cell Proliferation/genetics ; Down-Regulation/genetics ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Mice, Inbred BALB C ; Middle Aged ; Neoplasm Invasiveness ; PTEN Phosphohydrolase/antagonists & inhibitors ; Prognosis ; Mice
References:
Eur J Med Chem. 2018 Jan 20;144:82-92. (PMID: 29268133)
J Biol Chem. 2016 Jun 10;291(24):12851-12861. (PMID: 27129283)
Anticancer Drugs. 2014 Nov;25(10):1129-40. (PMID: 25035961)
Int J Oncol. 2015 Nov;47(5):1971-80. (PMID: 26398661)
Cell Death Dis. 2013 Oct 10;4:e847. (PMID: 24113181)
Cancer Treat Rev. 2019 Jan;72:45-55. (PMID: 30476750)
Oncogene. 2008 Sep 18;27(41):5527-41. (PMID: 18794886)
Oncotarget. 2016 Oct 4;7(40):66310-66322. (PMID: 27579619)
Cancer. 2016 Mar 15;122(6):842-51. (PMID: 26773572)
Mol Vis. 2018 Jul 23;24:485-494. (PMID: 30967746)
Biochem Biophys Res Commun. 2009 Sep 18;387(2):348-52. (PMID: 19595668)
Blood. 2013 Sep 26;122(13):2146-7. (PMID: 24072847)
CA Cancer J Clin. 2018 Jan;68(1):7-30. (PMID: 29313949)
Blood. 2013 Sep 26;122(13):2242-50. (PMID: 23869088)
Cancer Med. 2018 Aug;7(8):3763-3772. (PMID: 30022623)
Biomed Pharmacother. 2017 Oct;94:1094-1100. (PMID: 28821160)
Tumour Biol. 2015 Jan;36(1):383-91. (PMID: 25266796)
Int J Cancer. 1993 Sep 30;55(3):419-21. (PMID: 8375926)
Eur Urol. 2017 Jan;71(1):96-108. (PMID: 27370177)
Oncogene. 2008 Sep 18;27(41):5477-85. (PMID: 18794882)
Nature. 2020 Jan;577(7789):260-265. (PMID: 31853061)
Eur Urol. 2014 Apr;65(4):778-92. (PMID: 24373477)
Oncotarget. 2017 Oct 9;8(54):93001-93013. (PMID: 29190973)
Nature. 2004 Jul 8;430(6996):218-22. (PMID: 15241416)
J Invest Dermatol. 2012 Aug;132(8):2050-9. (PMID: 22513784)
J Crohns Colitis. 2014 Oct;8(10):1208-16. (PMID: 24637010)
Oncol Rep. 2020 Jun;43(6):1885-1896. (PMID: 32236585)
Cancer Gene Ther. 2020 Aug;27(7-8):607-618. (PMID: 31570754)
Mol Biosyst. 2015 Jul;11(7):1946-54. (PMID: 25924008)
Aging (Albany NY). 2015 Dec;7(12):1032-49. (PMID: 26655726)
J Natl Cancer Inst. 1999 Nov 3;91(21):1820-8. (PMID: 10547389)
PLoS One. 2015 Mar 23;10(3):e0121547. (PMID: 25799148)
BMC Cancer. 2019 Apr 25;19(1):391. (PMID: 31023264)
Nature. 2002 Dec 19-26;420(6917):860-7. (PMID: 12490959)
Biochem Pharmacol. 2019 Jul;165:24-32. (PMID: 30825432)
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1825-1829. (PMID: 30060954)
Biomed Res. 2015;36(2):103-7. (PMID: 25876660)
Infect Genet Evol. 2018 Apr;59:126-131. (PMID: 29407193)
Cell Cycle. 2016;15(4):573-83. (PMID: 26794644)
Semin Cancer Biol. 2019 Dec;59:147-160. (PMID: 31128298)
Eur Urol. 2015 Aug;68(2):238-53. (PMID: 25709027)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Immunohorizons. 2019 May 16;3(5):172-185. (PMID: 31356171)
Sci Rep. 2017 Jul 24;7(1):6348. (PMID: 28740238)
Annu Rev Biophys. 2013;42:443-68. (PMID: 23495970)
Adv Cancer Res. 2009;102:19-65. (PMID: 19595306)
Genes Dev. 2009 Mar 15;23(6):675-80. (PMID: 19261747)
Mol Diagn Ther. 2019 Oct;23(5):627-633. (PMID: 31267486)
EBioMedicine. 2019 Dec;50:238-245. (PMID: 31735557)
Annu Rev Immunol. 1996;14:649-83. (PMID: 8717528)
Methods Mol Biol. 2018;1655:335-350. (PMID: 28889395)
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66. (PMID: 17237035)
Contributed Indexing:
Keywords: NF‑κB inhibitor ζ; PTEN; bladder cancer; invasion; migration; proliferation
Substance Nomenclature:
0 (Adaptor Proteins, Signal Transducing)
0 (NFKBIZ protein, human)
EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
EC 3.1.3.67 (PTEN Phosphohydrolase)
Entry Date(s):
Date Created: 20210428 Date Completed: 20211111 Latest Revision: 20240226
Update Code:
20240226
PubMed Central ID:
PMC8057294
DOI:
10.3892/ijmm.2021.4942
PMID:
33907827
Czasopismo naukowe
NF‑κB inhibitor ζ (NFKBIZ), a member of the IκB family that interacts with NF‑κB, has been reported to be an important regulator of inflammation, cell proliferation and survival. However, the role of NFKBIZ in bladder cancer (BC) remains unknown. The present study aimed to investigate the functions of NFKBIZ in BC. First, the expression levels of NFKBIZ and the associations between NFKBIZ expression and the clinical survival of patients were determined using BC tissue samples, BC cell lines and datasets from different databases. Two BC cell lines (T24 and 5637) were selected to overexpress NFKBIZ, and the proliferative, migratory and invasive abilities of cells were determined; additionally, tumor growth following transplantation in in vivo mouse models was analyzed using T24 cells overexpressing NFKBIZ. Subsequently, the association between NFKBIZ and PTEN was determined using data from databases and immunohistochemistry analysis of clinical and nude mice tumor tissues. Finally, the interactions between NFKBIZ, PTEN and the downstream PI3K/AKT/mTOR signaling pathway were evaluated using western blotting. In conclusion, the present results indicated that NFKBIZ expression was low in BC, and NFKBIZ inhibited the proliferation of BC cells through the PTEN/PI3K/Akt signaling pathway, suggesting that NFKBIZ may represent a novel prognostic biomarker in BC and may provide a potential therapeutic tumor‑associated antigen for BC.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies